OncoMatch/Blood Cancer — Myelodysplastic (MDS)/IDH2
Blood Cancer — Myelodysplastic (MDS)IDH2 Clinical Trials
IDH2 mutations occur in approximately 8% of MDS and share the 2-HG-mediated differentiation block mechanism with IDH1 mutations. Enasidenib (IDH2 inhibitor) and vorasidenib (pan-IDH inhibitor) have been studied in IDH2-mutant MDS. Trials investigate IDH2-selective and pan-IDH inhibitor combinations with hypomethylating agents for IDH2-mutant MDS across risk categories.
Top recruiting IDH2 Blood Cancer — Myelodysplastic (MDS) trials
Ranked by phase and US site count. See all 5 trials matched to your profile →
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
M.D. Anderson Cancer Center
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
Heinrich-Heine University, Duesseldorf
A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.